April Berlyoung, PhD
Mary Ellen Gill
Board of Directors
HEMEMICS' technology can rapidly transform the $6B blood culture and $20B immunoassay testing markets.
To find out more about how the HEMEMICS technology can uniquely address COVID-19 and other diagnostic challenges, contact us.